Cogent Biosciences (COGT) Interest & Investment Income (2017 - 2026)
Cogent Biosciences (COGT) posted quarterly Interest & Investment Income of -$770000.0 for Q1 2026, down 126.08% year-over-year from $3.0 million in Q1 2025, and up 91.72% quarter-over-quarter from -$9.3 million in Q4 2025.
Powered by 
Analysis
Cogent Biosciences (COGT) Interest & Investment Income (2017 - 2026) Analysis & Trends
Cogent Biosciences (COGT) has reported Interest & Investment Income for 10 consecutive years, with -$770000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest & Investment Income fell 126.08% year-over-year to -$770000.0; the TTM figure through Mar 2026 stood at -$6.3 million (down 129.72% YoY), while the FY2025 annual figure was -$92000.0, down 100.51% from the prior year.
- Interest & Investment Income climbed to -$770000.0 in Q1 2026 per COGT's latest filing, from -$9.3 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $17.4 million in Q4 2024 and bottomed at -$9.3 million in Q4 2025.
- Historically, Interest & Investment Income has averaged $1.2 million across 5 years, with a median of $120000.0 in 2023.
- On a YoY basis, Interest & Investment Income climbed as much as 4071.77% in 2024 and fell as far as 337.5% in 2024.
- Cogent Biosciences' Interest & Investment Income stood at $4.2 million in 2022, then slumped by 89.93% to $418000.0 in 2023, then soared by 4071.77% to $17.4 million in 2024, then sank by 153.35% to -$9.3 million in 2025, then soared by 91.72% to -$770000.0 in 2026.
- Business Quant data shows COGT's Interest & Investment Income at -$770000.0 in Q1 2026, -$9.3 million in Q4 2025, and $3.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.26 Bn | 131.41 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 57.83 Bn | 52.69 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 39.94 Bn | 34.84 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.19 Bn | 31.88 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Cogent Biosciences | 5.94 Bn | 5.94 Bn | - | 7.46 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7.46 Mn |
| Mar 31, 2026 | 7.61 Mn |
| Dec 31, 2025 | 5.48 Mn |
| Sep 30, 2025 | 3.89 Mn |
| Jun 30, 2025 | 2.37 Mn |
| Mar 31, 2025 | 2.95 Mn |
| Dec 31, 2024 | 3.86 Mn |
| Sep 30, 2024 | 4.78 Mn |
| Jun 30, 2024 | 5.39 Mn |
| Mar 31, 2024 | 4.06 Mn |
| Dec 31, 2023 | 3.87 Mn |
| Sep 30, 2023 | 4.20 Mn |
| Jun 30, 2023 | 2.74 Mn |
| Mar 31, 2023 | 2.27 Mn |
| Dec 31, 2022 | 2.11 Mn |
| Sep 30, 2022 | 1.50 Mn |
| Jun 30, 2022 | 272,000.00 |
| Mar 31, 2022 | 107,000.00 |
| Dec 31, 2021 | 107,000.00 |
| Sep 30, 2021 | 115,000.00 |